Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Not Applicable
Completed
- Conditions
- Prostatic NeoplasmsBone Density
- Registration Number
- NCT00489905
- Lead Sponsor
- Hospital Authority, Hong Kong
- Brief Summary
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
- Prostate cancer patients aged between 50-80 who is having or will have ADT. Baseline BMD in between -2 standard deviation (SD) and mean of that among young adults.
Exclusion Criteria
- Patients with renal or liver problems, on calcium or other bisphosphonate therapy within six months before enrolling into the study.
Patients who have:
- Serum creatinine levels >212 µmol/L (2.4 mg/dL).
- Creatinine clearance <50 ml/min.
- WBC <4.0x109/L, Hgb <10 g/dL, platelets <140x109/L. Patients with known hypersensitivity to bisphosphonates. Patients with history of diseases with influence on bone metabolism, such as Page's disease of bone, primary hyperparathyroidism or osteoporosis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Bone mineral density of femoral neck 12 months after administration of zolderonic acid Bone mineral density of lumber spine 12 months after administration of zolderonic acid
- Secondary Outcome Measures
Name Time Method Change in creatinine clearance From time of enrollment to 3 months after the last intervention Change in serum creatinine, calcium, phosphate and alkaline phosphatase From time of enrollment to 3 months after the last intervention
Trial Locations
- Locations (1)
Department of Urology, Prince of Wales Hospital
🇨🇳Hong Kong, China